Zacks Investment Research upgraded shares of Marinus Pharmaceuticals (NASDAQ:MRNS) from a sell rating to a hold rating in a research note issued to investors on Wednesday morning.
According to Zacks, “Marinus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on developing and commercializing therapeutics for the treatment of epilepsy and other targeted neurological, behavioral and psychiatric disorders. The Company offers Ganaxolone which has completed Phase II clinical trial for the treatment of patients with refractory focal onset seizures. Marinus Pharmaceuticals, Inc. is headquartered in New Haven, Connecticut. “
Several other equities analysts have also recently issued reports on MRNS. BidaskClub cut shares of Marinus Pharmaceuticals from a strong-buy rating to a buy rating in a research note on Friday, June 22nd. ValuEngine cut shares of Marinus Pharmaceuticals from a buy rating to a hold rating in a research note on Saturday, October 6th. Cantor Fitzgerald set a $19.00 price target on shares of Marinus Pharmaceuticals and gave the stock a buy rating in a research note on Wednesday, August 8th. Finally, Mizuho reaffirmed a buy rating and set a $13.00 price target on shares of Marinus Pharmaceuticals in a research note on Thursday, August 2nd. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus price target of $19.67.
Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.09). On average, equities analysts expect that Marinus Pharmaceuticals will post -0.73 EPS for the current year.
Several large investors have recently bought and sold shares of MRNS. BlackRock Inc. grew its stake in shares of Marinus Pharmaceuticals by 316.9% during the 2nd quarter. BlackRock Inc. now owns 2,650,612 shares of the biopharmaceutical company’s stock worth $18,740,000 after purchasing an additional 2,014,774 shares during the period. VHCP Management II LLC acquired a new position in shares of Marinus Pharmaceuticals during the 2nd quarter worth $2,441,000. Northern Trust Corp grew its stake in shares of Marinus Pharmaceuticals by 625.7% during the 2nd quarter. Northern Trust Corp now owns 386,864 shares of the biopharmaceutical company’s stock worth $2,736,000 after purchasing an additional 333,555 shares during the period. JPMorgan Chase & Co. acquired a new position in shares of Marinus Pharmaceuticals during the 1st quarter worth $373,000. Finally, Bank of New York Mellon Corp grew its stake in shares of Marinus Pharmaceuticals by 190.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 106,560 shares of the biopharmaceutical company’s stock worth $754,000 after purchasing an additional 69,863 shares during the period. 63.64% of the stock is currently owned by institutional investors and hedge funds.
About Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three different dose forms: intravenous (IV), capsule, and liquid.
Featured Article: Fundamental Analysis – How It Helps Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.